SB
CBAY

Strategic Blueprint’s Cymabay Therapeutics CBAY Stock Holding History

Strategic Blueprint’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-15,800
Closed -$373K – 624
2023
Q4 		$373K Sell
15,800
-1,000
-6% -$17.8K 0.03% 402
2023
Q3 		$250K Buy
16,800
+1,000
+6% +$13.3K 0.02% 461
2023
Q2 		$173K Hold
15,800
– – 0.02% 526
2023
Q1 		$138K Sell
15,800
-2,400
-13% -$19.2K 0.01% 500
2022
Q4 		$114K Hold
18,200
– – 0.01% 497
2022
Q3 		$64K Buy
+18,200
New +$65.4K 0.01% 480

Other funds holding CBAY

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Strategic Blueprint's CBAY Position: Q1 2024 in Review

Strategic Blueprint sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 15,800 shares — an estimated $373K sold.

Strategic Blueprint first reported a position in CBAY in Q3 2022 and held it in 6 quarters. The position peaked at $373K in Q4 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

  • Strategic Blueprint reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Strategic Blueprint sold 15,800 Cymabay Therapeutics shares in Q1 2024, an estimated $373K.
  • Strategic Blueprint first reported a position in Cymabay Therapeutics in Q3 2022 and held it in 6 quarters.
  • Strategic Blueprint's Cymabay Therapeutics position peaked at $373K in Q4 2023.
  • 1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on Strategic Blueprint's 13F filing for Q1 2024, filed 23 Apr 2024.